Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-09-24, Stock:JNJ, The news for the past five days is as follows:
2018-09-17: NEWS1: Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV.NEWS2: Pfizer&apos;s Skin Disease Candidates Positive in Mid-Stage Study.NEWS3: J&J Talc Supplier Takes No Chances on Another Big Jury Loss.NEWS4: Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again.NEWS5: Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again.NEWS6: Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again.NEWS7: Is Artificial Intelligence the Next Big Thing in Biotech?.NEWS8: Is Artificial Intelligence the Next Big Thing in Biotech?.NEWS9: Is Artificial Intelligence the Next Big Thing in Biotech?.
2018-09-18: NEWS1: Health care ETF surges toward record in a broad sector rally.NEWS2: Cronos Gets Bigger As It Partners With Ginkgo Bioworks.NEWS3: Cronos Gets Bigger As It Partners With Ginkgo Bioworks.NEWS4: Exclusive - India, U.S. closing in on package deal to remove trade irritants.NEWS5: Cronos Gets Bigger As It Partners With Ginkgo Bioworks.NEWS6: Pharma Companies Avoid $3.8 Bln In Tax Per Year, Says Oxfam.NEWS7: Pharma Companies Avoid $3.8 Bln In Tax Per Year, Says Oxfam.NEWS8: Pfizer's Skin Disease Candidates Positive in Mid-Stage Study.NEWS9: Pfizer's Skin Disease Candidates Positive in Mid-Stage Study.NEWS10: Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV.NEWS11: Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV.
2018-09-19: NEWS1: Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results.NEWS2: 5 Dividend Stocks With 50-Plus Years of Annual Dividend Hikes.NEWS3: 5 Dividend Stocks With 50-Plus Years of Annual Dividend Hikes.NEWS4: Taking Stock of Quest Diagnostics’ Recent Acquisitions.NEWS5: How Quest Diagnostics Is Positioned in 2018.NEWS6: J&J Files NDA for Erdafitinib in Urothelial Cancer Indication.NEWS7: J&J Files NDA for Erdafitinib in Urothelial Cancer Indication.NEWS8: J&J Files NDA for Erdafitinib in Urothelial Cancer Indication.NEWS9: Pharma Stocks: Pfizer’s Revenue Trend and 2018 Estimates.NEWS10: The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering.NEWS11: Aduro's Cancer Arm & Strong Collaborations Boost Growth.NEWS12: Aduro's Cancer Arm & Strong Collaborations Boost Growth.
2018-09-20: NEWS1: 'We're ahead of the pack' in the cannabinoid drug space, says CEO of synthetic drugmaker Corbus.NEWS2: 7 Dow Jones Stocks Leading the Push to New Highs.NEWS3: Here’s a clear case for owning dividend stocks instead of bonds.NEWS4: Analysts Are Overwhelmingly Bullish on Abbott Laboratories.NEWS5: Lake Nona appears set to land big biotech facility.NEWS6: What Quest Diagnostics’ Valuation Trend Indicates.NEWS7: Pharma Stocks: Merck & Co.’s Revenue Trend and 2018 Estimates.
2018-09-21: NEWS1: Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression.NEWS2: How Does Sage Therapeutics’ Product Portfolio Look in September?.NEWS3: Notable ETF Inflow Detected - QUAL, JNJ, V, XOM.NEWS4: Notable ETF Inflow Detected - QUAL, JNJ, V, XOM.NEWS5: Is Abbott Laboratories Trading at a High Valuation in September?.NEWS6: See what the IHS Markit Score report has to say about Johnson & Johnson..NEWS7: Abbott Laboratories’ 379th Consecutive Quarterly Dividend.

Answer: Decrease